Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.64 |
| ▸ | NPC1 | O15118 | 4/20 | 0.64 |
| ▸ | MAOB | P27338 | 2/20 | 0.64 |
| ▸ | CTNNB1 | P35222 | 8/20 | 0.61 |
| ▸ | WNT3A | P56704 | 4/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.54 |
| ▸ | FEN1 | P39748 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30387529 | 0.87 | MAOB (0.65) | RAB9ANPC1MAOBCTNNB1WNT3A | |
| SCHEMBL26095520 | 0.87 | MAOB (0.65) | RAB9ANPC1MAOBCTNNB1WNT3A | |
| SCHEMBL10027735 | 0.85 | CTNNB1 (0.82) | RAB9ANPC1MAOBCTNNB1WNT3A | |
| SCHEMBL29962144 | 0.81 | ERCC5 (0.76) | RAB9ANPC1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL11791699 | 0.81 | ERCC5 (0.76) | RAB9ANPC1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL1535157 | 0.78 | ATM (0.72) | RAB9ANPC1CTNNB1WNT3AATM | |
| SCHEMBL21980363 | 0.78 | NPC1 (0.57) | RAB9ANPC1MAOBCTNNB1WNT3A | |
| SCHEMBL26728280 | 0.77 | ATM (0.71) | RAB9ANPC1CTNNB1WNT3AATM | |
| SCHEMBL10726266 | 0.76 | ALDH1A1 (0.69) | RAB9ANPC1MAOBKDM4ESMN1; SMN2 | |
| SCHEMBL2237626 | 0.76 | MEN1 (0.76) | RAB9ANPC1MAOBCTNNB1WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3634403-B1 | PHENYL-HETEROCYCLE-PHENYL DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF MELANOMA | MAX PLANCK GESELLSCHAFT (DE) | 2025-06-25 | — | — | EP | disclosed |
| US-11180518-B2 | Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-11-23 | — | — | US | disclosed |
| US-11180518-B2 | Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-11-23 | — | — | US | disclosed |
| US-20200165279-A1 | PHENYL-HETEROCYCLE-PHENYL DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF MELANOMA | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-05-28 | — | — | US | disclosed |
| US-20200165279-A1 | PHENYL-HETEROCYCLE-PHENYL DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF MELANOMA | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165279-A1 | PHENYL-HETEROCYCLE-PHENYL DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF MELANOMA | TYR, MITF, VHL | RAB9A 2195/4885NPC1 1279/4885MAOB 83/4885 |
| US-11180518-B2 | Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma | TYR, MITF, VHL | RAB9A 2195/4885NPC1 1279/4885MAOB 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.